Regeneron initiates trial for pozelimab + cemdisiran in PNH patients unresponsive to C5 inhibitors
Regeneron is conducting a study to evaluate the efficacy of pozelimab and cemdisiran in PNH patients inadequately controlled by existing therapies.
| Drug | MOA / Company | Stage |
|---|---|---|
| eculizumab | Regeneron | Lead |
| ravulizumab | — | Competing |
Focal Asset
eculizumab
Company
Regeneron
Indication
Hematology / Paroxysmal Nocturnal Hemoglobinuria (PNH)
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
Success in this trial may position Regeneron as a leader in PNH treatment options, potentially reshaping treatment paradigms and impacting market share.
Why it matters
The initiation of this trial by Regeneron represents a significant development in the treatment landscape for PNH, particularly for patients unresponsive to existing therapies. If successful, this combination therapy could disrupt the current market dominated by C5 inhibitors, enhancing Regeneron's competitive positioning.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results for efficacy and safety, as well as any announcements regarding patient recruitment and interim findings.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.